This company has been marked as potentially delisted and may not be actively trading.

Travere Therapeutics (RTRX) Competitors

RTRX vs. MANE, KLRA, GMTX, MOR, and ZYME

Should you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include MANE (MANE), Kailera Therapeutics (KLRA), Gemini Therapeutics (GMTX), MorphoSys (MOR), and Zymeworks (ZYME).

How does Travere Therapeutics compare to MANE?

Travere Therapeutics (NASDAQ:RTRX) and MANE (NYSE:MANE) are both pharmaceutical preparations industry companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

: MANE has a consensus target price of $83.33, indicating a potential downside of 27.27%. Given MANE's stronger consensus rating and higher possible upside, analysts plainly believe MANE is more favorable than Travere Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Travere Therapeutics
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
MANE
0 Sell rating(s)

1 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.80
: In the previous week, MANE had 3 more articles in the media than Travere Therapeutics. MarketBeat recorded 4 mentions for MANE and 1 mentions for Travere Therapeutics. MANE's average media sentiment score of 0.92 beat Travere Therapeutics' score of 0.00 indicating that MANE is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Travere Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
MANE
1 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: MANE has a net margin of 0.00% compared to Travere Therapeutics' net margin of -49.13%. MANE's return on equity of 0.00% beat Travere Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Travere Therapeutics -49.13% -36.38% -14.90%
MANE N/A N/A N/A
: MANE has lower revenue, but higher earnings than Travere Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Travere Therapeutics $175.34M 9.22 -$146.43M -$3.46 N/A
MANE N/A N/A N/A N/A N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MANE	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MANE	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-49.13%	-36.38%	-14.90%
MANE	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$175.34M	9.22	-$146.43M	-$3.46	N/A
MANE	N/A	N/A	N/A	N/A	N/A

Summary

MANE beats Travere Therapeutics on 8 of the 9 factors compared between the two stocks.

How does Travere Therapeutics compare to Kailera Therapeutics?

Travere Therapeutics (NASDAQ:RTRX) and Kailera Therapeutics (NASDAQ:KLRA) are both pharmaceutical preparations industry companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

: In the previous week, Travere Therapeutics and Travere Therapeutics both had 1 articles in the media. Travere Therapeutics' average media sentiment score of 0.00 equaled Kailera Therapeutics'average media sentiment score.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Travere Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Kailera Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Kailera Therapeutics has a net margin of 0.00% compared to Travere Therapeutics' net margin of -49.13%. Kailera Therapeutics' return on equity of 0.00% beat Travere Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Travere Therapeutics -49.13% -36.38% -14.90%
Kailera Therapeutics N/A N/A N/A
: Kailera Therapeutics has lower revenue, but higher earnings than Travere Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Travere Therapeutics $175.34M 9.22 -$146.43M -$3.46 N/A
Kailera Therapeutics N/A N/A N/A N/A N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kailera Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-49.13%	-36.38%	-14.90%
Kailera Therapeutics	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$175.34M	9.22	-$146.43M	-$3.46	N/A
Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A

Summary

Kailera Therapeutics beats Travere Therapeutics on 3 of the 4 factors compared between the two stocks.

How does Travere Therapeutics compare to Gemini Therapeutics?

Travere Therapeutics (NASDAQ:RTRX) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

: 75.4% of Gemini Therapeutics shares are owned by institutional investors. 4.6% of Travere Therapeutics shares are owned by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
: Travere Therapeutics has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the S&P 500.
: In the previous week, Travere Therapeutics and Travere Therapeutics both had 1 articles in the media. Travere Therapeutics' average media sentiment score of 0.00 equaled Gemini Therapeutics'average media sentiment score.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Travere Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Gemini Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Gemini Therapeutics has lower revenue, but higher earnings than Travere Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Travere Therapeutics $175.34M 9.22 -$146.43M -$3.46 N/A
Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A
: Gemini Therapeutics has a net margin of 0.00% compared to Travere Therapeutics' net margin of -49.13%. Travere Therapeutics' return on equity of -36.38% beat Gemini Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Travere Therapeutics -49.13% -36.38% -14.90%
Gemini Therapeutics N/A -38.78% -35.88%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gemini Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$175.34M	9.22	-$146.43M	-$3.46	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-49.13%	-36.38%	-14.90%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Summary

Travere Therapeutics and Gemini Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Travere Therapeutics compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Travere Therapeutics (NASDAQ:RTRX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

: 18.4% of MorphoSys shares are held by institutional investors. 0.1% of MorphoSys shares are held by insiders. Comparatively, 4.6% of Travere Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
: MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.
: In the previous week, Travere Therapeutics had 1 more articles in the media than MorphoSys. MarketBeat recorded 1 mentions for Travere Therapeutics and 0 mentions for MorphoSys. MorphoSys' average media sentiment score of 0.00 equaled Travere Therapeutics'average media sentiment score.
Company Overall Sentiment
MorphoSys Neutral
Travere Therapeutics Neutral
: Travere Therapeutics has lower revenue, but higher earnings than MorphoSys. Travere Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A
Travere Therapeutics $175.34M 9.22 -$146.43M -$3.46 N/A
: Travere Therapeutics has a net margin of -49.13% compared to MorphoSys' net margin of -226.79%. Travere Therapeutics' return on equity of -36.38% beat MorphoSys' return on equity.
Company Net Margins Return on Equity Return on Assets
MorphoSys -226.79% -694.31% -22.55%
Travere Therapeutics -49.13% -36.38% -14.90%

Company	Overall Sentiment
MorphoSys	Neutral
Travere Therapeutics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Travere Therapeutics	$175.34M	9.22	-$146.43M	-$3.46	N/A

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Travere Therapeutics	-49.13%	-36.38%	-14.90%

Summary

Travere Therapeutics beats MorphoSys on 7 of the 12 factors compared between the two stocks.

How does Travere Therapeutics compare to Zymeworks?

Zymeworks (NASDAQ:ZYME) and Travere Therapeutics (NASDAQ:RTRX) are both small-cap pharmaceutical preparations industry companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

: Zymeworks currently has a consensus target price of $37.89, indicating a potential upside of 42.01%. Given Zymeworks' stronger consensus rating and higher possible upside, equities research analysts clearly believe Zymeworks is more favorable than Travere Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zymeworks
1 Sell rating(s)
1 Hold rating(s)

9 Buy rating(s)

2 Strong Buy rating(s)
2.92
Travere Therapeutics
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Zymeworks has higher earnings, but lower revenue than Travere Therapeutics. Zymeworks is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zymeworks $105.96M 18.57 -$81.13M -$1.08 N/A
Travere Therapeutics $175.34M 9.22 -$146.43M -$3.46 N/A
: In the previous week, Zymeworks had 2 more articles in the media than Travere Therapeutics. MarketBeat recorded 3 mentions for Zymeworks and 1 mentions for Travere Therapeutics. Zymeworks' average media sentiment score of 0.45 beat Travere Therapeutics' score of 0.00 indicating that Zymeworks is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zymeworks
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Travere Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 92.9% of Zymeworks shares are owned by institutional investors. 33.5% of Zymeworks shares are owned by company insiders. Comparatively, 4.6% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: Travere Therapeutics has a net margin of -49.13% compared to Zymeworks' net margin of -76.56%. Zymeworks' return on equity of -26.00% beat Travere Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Zymeworks -76.56% -26.00% -20.57%
Travere Therapeutics -49.13% -36.38% -14.90%
: Zymeworks has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92
Travere Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96M	18.57	-$81.13M	-$1.08	N/A
Travere Therapeutics	$175.34M	9.22	-$146.43M	-$3.46	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Travere Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-76.56%	-26.00%	-20.57%
Travere Therapeutics	-49.13%	-36.38%	-14.90%

Summary

Zymeworks beats Travere Therapeutics on 13 of the 17 factors compared between the two stocks.

Get Travere Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RTRX vs. The Competition

Export

Metric	Travere Therapeutics	Pharmaceutical Preparations Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.62B	$886.55M	$6.25B	$11.77B
Dividend Yield	N/A	4.84%	2.74%	5.26%
P/E Ratio	-15.01	1.71	29.25	27.07
Price / Sales	9.22	120.63	504.68	73.47
Price / Cash	N/A	20.07	43.30	53.90
Price / Book	6.15	7.60	9.67	6.69
Net Income	-$146.43M	-$4.80M	$3.55B	$332.64M

Travere Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RTRX Travere Therapeutics	N/A	$31.68 +0.0%	N/A	N/A	$1.62B	$175.34M	N/A	221	Gap Up High Trading Volume
MANE MANE	N/A	$101.58 +2.6%	$83.33 -18.0%	N/A	$3.79B	N/A	N/A	19	High Trading Volume
KLRA Kailera Therapeutics	N/A	$25.15 +0.6%	N/A	N/A	$3.11B	N/A	N/A	145
GMTX Gemini Therapeutics	N/A	$66.91 +1.5%	N/A	N/A	$2.90B	N/A	N/A	30	High Trading Volume
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RTRX) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Travere Therapeutics (RTRX) Competitors

RTRX vs. MANE, KLRA, GMTX, MOR, and ZYME

How does Travere Therapeutics compare to MANE?

Summary

How does Travere Therapeutics compare to Kailera Therapeutics?

Summary

How does Travere Therapeutics compare to Gemini Therapeutics?

Summary

How does Travere Therapeutics compare to MorphoSys?

Summary

How does Travere Therapeutics compare to Zymeworks?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RTRX vs. The Competition

Travere Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Travere Therapeutics (RTRX) Competitors

RTRX vs. MANE, KLRA, GMTX, MOR, and ZYME

How does Travere Therapeutics compare to MANE?

Summary

How does Travere Therapeutics compare to Kailera Therapeutics?

Summary

How does Travere Therapeutics compare to Gemini Therapeutics?

Summary

How does Travere Therapeutics compare to MorphoSys?

Summary

How does Travere Therapeutics compare to Zymeworks?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RTRX vs. The Competition

Travere Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools